Advanced

Growth Hormone Safety Workshop Position Paper: a critical appraisal of recombinant human growth hormone therapy in children and adults.

Allen, David B; Backeljauw, Philippe; Bidlingmaier, Martin; Biller, Beverly; Boguszewski, Margaret; Burman, Pia LU ; Butler, Gary; Chihara, K; Christiansen, Jens Sandahl and Cianfarani, Stefano, et al. (2015) In European Journal of Endocrinology
Abstract
Recombinant human growth hormone (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety including; cancer risk, impact on glucose homeostasis and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk and the need for longterm surveillance of the increasing number of adults who were treated with... (More)
Recombinant human growth hormone (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety including; cancer risk, impact on glucose homeostasis and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk and the need for longterm surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Endocrinology
publisher
Society of the European Journal of Endocrinology
external identifiers
  • pmid:26563978
  • scopus:84956654819
  • wos:000370244100001
ISSN
1479-683X
DOI
10.1530/EJE-15-0873
language
English
LU publication?
yes
id
d82498a1-3818-433c-b430-9ba3a87eba37 (old id 8235613)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26563978?dopt=Abstract
date added to LUP
2015-12-04 21:58:47
date last changed
2017-10-22 04:52:34
@article{d82498a1-3818-433c-b430-9ba3a87eba37,
  abstract     = {Recombinant human growth hormone (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety including; cancer risk, impact on glucose homeostasis and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk and the need for longterm surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.},
  author       = {Allen, David B and Backeljauw, Philippe and Bidlingmaier, Martin and Biller, Beverly and Boguszewski, Margaret and Burman, Pia and Butler, Gary and Chihara, K and Christiansen, Jens Sandahl and Cianfarani, Stefano and Clayton, Peter E and Clemmons, David and Cohen, Pinchas and Darendeliler, Feyza and Deal, Cheri and Dunger, David P and Erfurth, Eva Marie and Fuqua, John and Grimberg, Adda and Haymond, Morey and Higham, Claire and Ho, Ken K Y and Hoffman, Andrew R and Hokken-Koelega, Anita Cs and Johannsson, Gudmundur and Juul, Anders and Kopchick, John J and Lee, Peter and Pollak, Michael and Radovick, Sally and Robison, Leslie and Rosenfeld, Ron and Ross, Richard J and Savendahl, Lars and Saenger, Paul and Toft Sorensen, H and Stochholm, Kirstine and Strasburger, Christian J and Swerdlow, Anthony and Thorner, Michael O},
  issn         = {1479-683X},
  language     = {eng},
  month        = {11},
  publisher    = {Society of the European Journal of Endocrinology},
  series       = {European Journal of Endocrinology},
  title        = {Growth Hormone Safety Workshop Position Paper: a critical appraisal of recombinant human growth hormone therapy in children and adults.},
  url          = {http://dx.doi.org/10.1530/EJE-15-0873},
  year         = {2015},
}